Last reviewed · How we verify

Hydrofol — Competitive Intelligence Brief

Hydrofol (docosanoic acid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: docosanoic acid. Area: Metabolic.

unknown docosanoic acid Peroxisome proliferator-activated receptor delta, Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma Metabolic Live · refreshed every 30 min

Target snapshot

Hydrofol (docosanoic acid). Hydrofol works by activating the peroxisome proliferator-activated receptor alpha (PPAR-alpha), a protein that regulates the expression of genes involved in lipid metabolism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hydrofol TARGET docosanoic acid unknown docosanoic acid Peroxisome proliferator-activated receptor delta, Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (docosanoic acid class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydrofol — Competitive Intelligence Brief. https://druglandscape.com/ci/docosanoic-acid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing